China drug licensing deals for early-stage prospects are expected to rise, focusing on cell and gene therapies.
Author: PharmaSignal News Desk
Cormorant SPAC deal secures $150M for a new biotech merger, marking its third since 2022 amid a rebound in SPAC activity.
PharmaSignal Take This week’s events highlight a growing trend in the pharma industry towards strategic acquisitions and partnerships, particularly in the areas of immunotherapy and obesity treatment. Notable examples include Lilly’s acquisition of Ventyx and Corxel’s licensing deal for an obesity pill. These moves stress-test the assumption of platform scalability, suggesting a shift in post-approval decision-making towards a more integrated approach to product development and market access. This is the PharmaSignal Weekly Brief – Global Pharma Roundup, where we highlight the dominant themes of M&A activity, regulatory acceleration, and pipeline risk in the global pharma industry. M&A and Strategic Deals…
Corxel GLP-1 Obesity Pill receives $287M funding to support its development, licensed from Vincentage in China.
Bristol Myers partners with Janux in a deal worth up to $850 million, focusing on T cell engagers for cancer treatment.
FDA multiple myeloma drugs pathway accelerates approvals, allowing therapies to clear based on tumor cell elimination.
Johnson & Johnson sales are expected to reach $100B by 2025, driven by cancer and immune drugs, despite patent challenges.
Valneva Chikungunya vaccine is withdrawn from the US market following FDA suspension, raising concerns about its future.
PharmaSignal Take The week’s events signal a continued trend of strategic acquisitions and regulatory advancements in the pharma sector. The takeover talks between Oxford Biomedica and EQT, and the acquisition of Ventyx by Lilly, stress-test the assumption of platform scalability and integration risk. These developments have significant implications for post-close decision-making, particularly in terms of asset integration and portfolio expansion. This week’s PharmaSignal Weekly Brief – Global Pharma Roundup highlights an uptick in M&A activity, regulatory advancements, and pipeline developments. The dominant themes include strategic acquisitions, FDA approvals, and promising pipeline projects. M&A and Strategic Deals Oxford Biomedica engages in…
Oxford Biomedica EQT talks highlight the biotech investor’s interest, despite previous rejections of bids deemed undervalued.